GenesisCare has revealed plans to open a new cancer centre in Royal Tunbridge Wells, marking the independent provider’s seventh dedicated Systemic Anti-Cancer Therapy (SACT) facility in the UK.
The purpose-built centre, located at Century Place, is scheduled to open in autumn 2026.
“Planning permission has now been secured, allowing the project to advance to the tender stage. We anticipate appointing a contractor within the next 2-3 weeks, following the review of submissions,” a GenesisCare representative told Building Better Healthcare.
The development is designed to increase access to systemic cancer treatments for patients in West Kent, while reducing the need for travel to existing facilities.
The centre will deliver a full range of SACT services, including chemotherapy, immunotherapy and cellular therapies, within a modern clinical environment.
The announcement builds on GenesisCare’s established presence in Maidstone, where it has operated an oncology centre providing radiotherapy, systemic therapy and diagnostic services since 2015.
Why is GenesisCare focused on establishing new cancer centres?
According to GenesisCare, the new Tunbridge Wells facility responds to demand from local clinicians and forms part of the organisation’s wider strategy to expand cancer treatment capacity and improve regional accessibility.
The announcement comes amid wider efforts to improve cancer detection across England, including a new NHS world-first inherited cancer risk detection programme designed to regularly monitor people with genetic risk markers and speed up early screening and intervention.
What will the new centre offer?
GenesisCare also confirmed that Consultant Haematologist Dr Joel Newman will join the organisation as part of the expansion.
Dr Newman specialises in the treatment of haematological conditions, including leukaemia, myeloma and lymphoma, and currently treats patients across Kent and the South East.
In addition to systemic therapies, the centre will provide access to supportive care technologies, including Hilotherm, alongside integrated wellbeing services and exercise medicine programmes.
Hilotherm is a temperature-controlled cooling therapy system used during chemotherapy to help reduce treatment-related side effects, particularly chemotherapy-induced peripheral neuropathy.
GenesisCare stated that further announcements regarding UK service expansion will be made in due course.